ClinicalTrials.gg

Program

IDH1 Inhibitor TQB3454

Also written as “TQB3454 tablets”, “TQB3454 Tablets” and “TQB3454”.

In Sino Biopharmaceutical’s pipeline, IDH1抑制剂. Its studies are mostly in Leukemia, Myeloid, Acute, led by Sino Biopharmaceutical.

Furthest: phase 3, since Aug 4, 20235 company-led studies, 4 open or runningNext primary completion: Dec 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sino Biopharmaceutical54 open or runningphase 3since Aug 4, 2023Jul 19, 2020Dec 2026phase 3 · NCT05987358
  • Named in Sino Biopharmaceutical’s own pipeline as TQB3454, phase 3, as of Nov 16, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 19, 2020First study: phase 1 study in Advanced Solid Tumor or Hematologic TumorFirst studyNCT04481607 · 96 enrolled · China
  2. Aug 4, 2023Phase 3 study in Biliary CarcinomaNCT05987358 · 165 enrolled · China
  3. Nov 15, 2023Phase 1 study in Biliary CarcinomaNCT06139367 · 40 planned · China
  4. Jan 12, 2024Phase 2 study in Leukemia, Myeloid, AcuteNCT06218771 · 80 planned · China
  5. Jul 21, 2026Phase 2 study in Advanced Solid TumorsNCT07738679 · 127 planned · China

Ahead

  1. Dec 2026Primary completion: phase 3 study in Biliary CarcinomaNCT05987358
  2. Dec 2028Primary completion: phase 2 study in Advanced Solid TumorsNCT07738679

TargetBeta

“IDH1抑制剂”the company's pipeline, read by Claude · source
“An orally bioavailable, small molecule inhibitor of isocitrate dehydrogenase type 1 (IDH1; IDH-1; IDH1 [NADP+] soluble) mutant forms, ”NCIt, by rule

Other programs on IDH1

ProgramCompanyFurthest phaseStudies
olutasidenibruleRigel Pharmaceuticalsphase 45
ivosidenibruleAgios Pharmaceuticalsphase 313
vorasidenibruleAgios Pharmaceuticalsphase 312
ranosidenibruleHUTCHMEDphase 37
safusidenibruleNuvation Biophase 36

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07738679Advanced Solid Tumors · China2Not yet recruitingDec 2028127
NCT06218771Leukemia, Myeloid, Acute · China2RecruitingJun 202580
NCT06139367Biliary Carcinoma · China1Not yet recruitingDec 202340
NCT05987358Biliary Carcinoma · China3Active, not recruitingDec 2026165
NCT04481607Advanced Solid Tumor or Hematologic Tumor · China1UNKNOWNDec 31, 202296

How it is read

Names in the registry

  • “TQB3454 tablets”, 3 entries
  • “TQB3454 Tablets”, 1 entry
  • “TQB3454”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.